The Effects of Medical and Recreational Cannabis Laws on Prescription Drug Claims in Commercial Group Insurance Markets

Amanda C. Cook, E. Tice Sirmans and Rhet Smith

Health Economics, 2025, vol. 34, issue 8, 1396-1409

Abstract: Initially introduced as an alternative medical treatment, cannabis has been conditionally legalized in most U.S. states. Using prescription drug claims as reported by small and large group insurers in the NAIC Supplemental Health Care Exhibit from 2010–2019, we examine the impact of medical and recreational cannabis laws on prescription drug expenditures of working‐age individuals. We use a difference‐in‐differences framework and find significant reductions in prescription drug claims per enrollee of $34–42 annually in the small group insurance market following recreational cannabis legalization. While we do not observe similar reductions in claims in large group insurance markets, we find weak evidence that the reduced expenditures in small group insurance correspond with reductions in premiums indicating positive spillover effects from recreational cannabis for insured enrollees of small group insurance plans.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/hec.4967

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:34:y:2025:i:8:p:1396-1409

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().